AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32706124
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behavior therapy (CBT) for anxiety related to asthma
Trial: 32448894
Drug: Stopping prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping prophylaxis when the patient was virologically suppressed (two consecutive HIV RNA ≤ 400c/mL)
Trial: 35361632
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of methylprednisolone intravenously for 3 consecutive days
Trial: 33001206
Drug: Antibody titers
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody titers in sequential samples from serum donors recovering from COVID-19
Trial: 33068350
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of houttuynia cordata (3 mL each time, once a day for 3 injections, then once every two days for 3 times)
Trial: 33068350
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tears and anti-inflammatory drugs
Trial: 32446263
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (lower dosage) in cesarean-born neonates (CDL)
Trial: 32446263
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (higher dosage) in cesarean-born neonates (CDH)
Trial: 35217772
Drug: Exenatide 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2.0 mg once weekly plus dapagliflozin 10 mg once daily
Trial: 32091358
Drug: Accelerated vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated vaccine schedule (0 and 21 days)
Trial: 32091358
Drug: Longer interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer interval vaccine schedule (0 and 60 days)
Trial: 33122529
Drug: LMWH combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH combined with insulin
Trial: 35854638
Drug: Palovarotene 10/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene 10/5 mg
Trial: 35854638
Drug: Palovarotene 5/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene 5/2.5 mg
Trial: 34475143
Drug: Prepectoral implant-based
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepectoral implant-based breast reconstruction (IBBR)
Trial: 34475143
Drug: Subpectoral implant-based
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subpectoral implant-based breast reconstruction (IBBR)
Trial: 33415556
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and surgery
Trial: 33589674
Drug: Cocoa flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanols (260, 510, and 770 mg/day) for 12 weeks
Trial: 36069785
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral therapy (ICBT) course (5-week duration)
Trial: 36069785
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) before treatment
Trial: 36069785
Drug: Self-guided booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-guided booster lesson (1 month after treatment)
Trial: 32092190
Drug: Sleep hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep hygiene control (in-person discussion and monthly phone calls)
Trial: 34719577
Drug: Propranolol gel
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol gel 1%
Trial: 34719577
Drug: Propranolol gel
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol gel 5%
Trial: 34292643
Drug: ozanimod 0.46
RxNorm normalized name: ozanimod 0.46 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ozanimod 0.46 mg or 0.92 mg daily
Trial: 34292643
Drug: interferon β‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interferon β‐1a 30 µg weekly
Trial: 36429671
Drug: Bi-weekly resilience-enhancement
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly resilience-enhancement program (four 2-h sessions)
Trial: 33964898
Drug: Nomogram including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nomogram including T stage, N stage, grade, radiotherapy, and chemotherapy
Trial: 35145209
Drug: High loading
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High loading dose caffeine (80 mg/kg)
Trial: 35145209
Drug: Standard loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard loading dose caffeine (20 mg/kg)
Trial: 33715788
Drug: Ischemic pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ischemic pressure (IP) with traditional treatment
Trial: 33715788
Drug: Postisometric relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postisometric relaxation (PIR) with traditional treatment
Trial: 32929337
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group not specified, but implied standard treatment for UC.
Trial: 36432574
Drug: Quinoa-enriched wheat-bread
RxNorm normalized name: quinoa oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinoa-enriched wheat-bread roll providing 20 g quinoa flour each day
Trial: 34439234
Drug: Auricular acupuncture
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupuncture (10 treatments within five weeks)
Trial: 33047298
Drug: Dupilumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab with concomitant topical corticosteroids
Trial: 35932644
Drug: Comparison cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison cohort (initiating methadone treatment alone)
Trial: 32015261
Drug: 0.45 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/d oral conjugated equine estrogens (o-CEE)
Trial: 32015261
Drug: 50 mcg/d
RxNorm normalized name: Natpara 50 MCG/Dose Cartridge, 14 Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mcg/d transdermal 17β-estradiol (t-E2)
Trial: 36193494
Drug: Best Medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Medical Therapy (BMT) combined with Thoracic Endovascular Aortic Repair (TEVAR)
Trial: 32500194
Drug: Intra-articular facet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular facet steroid injection (IFSI)
Trial: 32500194
Drug: Transforaminal steroid
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal steroid injection (TFSI)
Trial: 32243719
Drug: Apple intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple intake (dose-response study)
Trial: 35111046
Drug: Standard-dose GHX02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose GHX02
Trial: 35111046
Drug: High-dose GHX02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GHX02 and Standard-dose GHX02
Trial: 33866196
Drug: Standard PD
RxNorm normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PD therapy
Trial: 34153117
Drug: Erenumab 70
RxNorm normalized name: Erenumab 70 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 70 mg once monthly
Trial: 32897933
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prednisolone per day for 1 week
Trial: 36179790
Drug: 120-second MicroPulse
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120-second MicroPulse Transscleral Laser Therapy (MPTLT)
Trial: 36179790
Drug: 100-second MicroPulse
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100-second MicroPulse Transscleral Laser Therapy (MPTLT)
Trial: 32576247
Drug: Individualized tonotopical
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized tonotopical fitting of a cochlear implant (CI) based on post-operative cone beam CT scan (CBCT)
Trial: 36050653
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg every 2 weeks)
Trial: 34774080
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine JCM-16021
Trial: 35926833
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) trivalent modified-live virus (MLV) respiratory vaccine with parenteral (PT) bivalent bovine viral diarrhea virus (BVDV) type I + II vaccine (INT)
Trial: 35926833
Drug: Parenteral (PT)
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral (PT) pentavalent modified-live virus (MLV) respiratory vaccine (INJ)
Trial: 35926833
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) trivalent modified-live virus (MLV) respiratory vaccine with parenteral (PT) BVDV type I + II vaccine (INT)
Trial: 32405975
Drug: Sugammadex (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (2 or 4 mg·kg‐1)
Trial: 32405975
Drug: Neostigmine (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (70 µg·kg‐1, maximum 5 mg)
Trial: 33025447
Drug: Free pharmaceutical
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free pharmaceutical services provided in public hospitals
Trial: 33491385
Drug: Single application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application of 1% NaF-HF gel
Trial: 33491385
Drug: Two applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two applications of 1% NaF-HF gel with a 7-day interval
Trial: 33491385
Drug: Two applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two applications of 1% NaF-HF gel with a 6-month interval
Trial: 32297937
Drug: Galactose (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galactose (0.75 g/kg body mass) in a high-fat beverage
Trial: 32297937
Drug: Glucose (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (0.75 g/kg body mass) in a high-fat beverage
Trial: 32297937
Drug: Fructose (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (0.75 g/kg body mass) in a high-fat beverage
Trial: 33196511
Drug: Anticoagulation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation and atorvastatin 40 mg daily
Trial: 33196511
Drug: Anticoagulation alone
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation alone (with either warfarin or rivaroxaban)
Trial: 32303884
Drug: Remimazolam induction
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam induction at 6 mg kg-1 h-1 (group A)
Trial: 32303884
Drug: Remimazolam induction
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam induction at 12 mg kg-1 h-1 (group B)
Trial: 32303884
Drug: Remimazolam maintenance
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam maintenance infusion up to 2 mg kg-1 h-1 for both groups
Trial: 35104848
Drug: Omilancor 440
RxNorm normalized name: Omilancor
DrugBank: Omilancor (DB19277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omilancor 440 mg QD
Trial: 35104848
Drug: Omilancor 880
RxNorm normalized name: Omilancor
DrugBank: Omilancor (DB19277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omilancor 880 mg QD
Trial: 33050924
Drug: Hydroxychloroquine 200
RxNorm normalized name: hydroxychloroquine 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 200 mg, 2 tablets BID on day 0, 2 tablets QD from day 1 to 9
Trial: 33050924
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg, 1 tablet QD from day 0 to 9
Trial: 33050924
Drug: Favipiravir 200
RxNorm normalized name: Favipiravir 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir 200 mg, 12 tablets BID on day 0, 6 tablets BID from day 1 to 9
Trial: 33050924
Drug: Telmisartan 20
RxNorm normalized name: telmisartan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 20 mg, 1 tablet QD from day 0 to 9
Trial: 33050924
Drug: Complex of
RxNorm normalized name: Binary complex of recombinant human insulin-like growth factor I and insulin-like growth factor binding protein 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex of vitamins and trace elements (AZINC Forme et Vitalité®), 1 capsule BID for 10 days
Trial: 32042407
Drug: Cod protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod protein hydrolysate (CPH) 10 mg/kg BW
Trial: 32042407
Drug: Cod protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod protein hydrolysate (CPH) 40 mg/kg BW
Trial: 32838661
Drug: Control (hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (hydration therapy)
Trial: 34036689
Drug: Group-cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-cognitive-behavioral therapy (CBT)
Trial: 38866963
Drug: Hyperthermic intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 35390490
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (regular activities of daily living)
Trial: 32897035
Drug: Continuous molgramostim
RxNorm normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous molgramostim (300 μg once daily by inhalation)
Trial: 34085873
Drug: Assessment and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment and feedback combined with vaccine communication training and behavioral nudges (vaccine commitment posters)
Trial: 34085873
Drug: Parents of
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents of HPV vaccine-hesitant children
Trial: 35295236
Drug: Lesogaberan 120
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan 120 mg modified release twice daily
Trial: 35928056
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg) on days one and two, followed by misoprostol (200 or 400 μg, vaginally, six-hourly, up to three doses in 12 h)
Trial: 35928056
Drug: Mifepristone (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (one dose on day one) followed by misoprostol on day three (historical control)
Trial: 35928056
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg) on days one and two, followed by misoprostol
Trial: 35797219
Drug: Additional anthracycline-containing
RxNorm normalized name: methacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Additional anthracycline-containing chemotherapy
Trial: 34039277
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application for monitoring patients under home oxygen therapy
Trial: 35217351
Drug: Cathodal high-definition
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal high-definition tDCS (treatment group)
Trial: 35215057
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenges (two per day for 90 days) with regular oral hygiene
Trial: 35215057
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges (two per day for 90 days) with regular oral hygiene
Trial: 34533249
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and ALES (artichoke leaf extract)
Trial: 34533249
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and Vitamin E
Trial: 35324339
Drug: Tapering group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering group
Trial: 33375899
Drug: Compassion-Focused Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compassion-Focused Therapy (CFT) - 8 sessions
Trial: 33375899
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - no therapy
Trial: 33091587
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group receiving EHR-based best practice alert and psychiatrist review of prescriptions.
Trial: 33149136
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis at the start of anti‐myeloma treatment
Trial: 34529869
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of transobturator tape sling (TOT) and low-dose Abobotulinumtoxin-A injection (300 U injected in 20–30 sites)
Trial: 34529869
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Part 2)
Trial: 33632930
Drug: Doxorubicin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin at 75 mg/m2 for eight cycles
Trial: 33632930
Drug: Doxorubicin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin at 75 mg/m2 for eight cycles with dexrazoxane coadministration
Trial: 35882292
Drug: CBD supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD supplement (Hemp Extract, 150 mg)
Trial: 35882292
Drug: Control (supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (supplement pellets without CBD)
Trial: 32664094
Drug: Intravenous phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phenylephrine infusion (0.5 μg/kg/min) for 5 minutes before BCP
Trial: 32664094
Drug: Intravenous phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phenylephrine infusion (1.0 μg/kg/min) for 5 minutes before BCP
Trial: 34261364
Drug: Methylnaltrexone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone (0.3 mg/kg IV)
Trial: 33350782
Drug: Pinaverium bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium bromide tablets placebo
Trial: 33350782
Drug: Pinaverium bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium bromide tablets
Trial: 36174595
Drug: Artemether-lumefantrine (3-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (3-day course of twice-daily dosing followed by weekly dosing for 4 weeks)
Trial: 36174595
Drug: Multivitamin (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin (no antimalarial activity)
Trial: 35509395
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen (HFNO) at 40 L min−1
Trial: 32838710
Drug: Capsinoids (CSN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsinoids (CSN) 12 mg, single dosage
Trial: 32838710
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules with a high‐carbohydrate meal (2 g carb/kg bodyweight)
Trial: 33256506
Drug: Breviscapine (BRE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breviscapine (BRE) 120 mg daily (40 mg, three times a day) for 14 days
Trial: 33256506
Drug: MDR1 C3435T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDR1 C3435T gene polymorphisms (CC, CT, TT genotypes)
Trial: 36319585
Drug: Olive leaf
RxNorm normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive leaf extract 250 mg every 12 hours for five days
Trial: 36319585
Drug: Olive leaf
RxNorm normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive leaf extract 500 mg every 12 hours for five days
Trial: 33888191
Drug: Moderate levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate levels of daily physical activity
Trial: 33888191
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of daily physical activity
Trial: 34399702
Drug: Physiotherapist-led management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapist-led management (Personalised Hip Therapy - PHT)